MAP2K7

Across TCGA pan-cancer cohorts, MAP2K7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP2K7 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MAP2K7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP2K7 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where MAP2K7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.849	0.599	.004	34	view →
PDAC	OS	Median	All	0.757	0.934	<.001	26	view →
CCRCC	OS	Median	III,IV	0.859	0.516	.001	18	view →
GBM	DFS	Median	All	0.450	0.297	.038	2	view →
LUAD	OS	Tertile	III,IV	1.000	0.852	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP2K7–LSCC (DFS)

Open the LSCC breakdown →